TrialPanorama/Dataset huggingface dataset:
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind Study Comparing the Safety & Efficacy of Once-Weekly Etanercept 50 mg, Etanercept 25 mg, & Placebo in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis
Brief Summary: To compare the efficacy of the combination of etanercept 50 mg once weekly plus methotrexate with that of methotrexate monotherapy in the treatment of rheumatoid arthritis over 88 weeks.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: Methotrexate | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1, 2, 3
B: Arm Label: 001; Type: EXPERIMENTAL; Interventions: Drug: Golimumab | Arm Label: 002; Type: EXPERIMENTAL; Interventions: Drug: Golimumab | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): 002 | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): 001
C: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 3
D: Arm Label: Abatacept; Type: EXPERIMENTAL; Interventions: Drug: Abatacept | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-Blind Study Comparing the Safety & Efficacy of Once-Weekly Etanercept 50 mg, Etanercept 25 mg, & Placebo in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis
Brief Summary: To compare the efficacy of the combination of etanercept 50 mg once weekly plus methotrexate with that of methotrexate monotherapy in the treatment of rheumatoid arthritis over 88 weeks.


Options:
A: Arm Label: TNF-blocking drug; Type: EXPERIMENTAL; Interventions: Drug: Etanercept, Drug: Adalimumab, Drug: Certolizumab Pegol, Drug: Infliximab, Drug: Golimumab | Arm Label: Abatacept; Type: EXPERIMENTAL; Interventions: Drug: Abatacept | Arm Label: Rituximab; Type: ACTIVE_COMPARATOR; Interventions: Biological: Rituximab | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): TNF-blocking drug | Intervention Type: DRUG; Name: Abatacept; Assigned to Arm(s): Abatacept | Intervention Type: BIOLOGICAL; Name: Rituximab; Assigned to Arm(s): Rituximab | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): TNF-blocking drug | Intervention Type: DRUG; Name: Certolizumab Pegol; Assigned to Arm(s): TNF-blocking drug | Intervention Type: DRUG; Name: Infliximab; Assigned to Arm(s): TNF-blocking drug | Intervention Type: DRUG; Name: Golimumab; Assigned to Arm(s): TNF-blocking drug
B: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Etanercept, Drug: Methotrexate | Arm Label: 3; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Methotrexate | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Etanercept; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): 3
C: Arm Label: methotrexate + adalimumab; Type: EXPERIMENTAL; Interventions: Drug: Adalimumab | Arm Label: methotrexate + placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: Adalimumab; Assigned to Arm(s): methotrexate + adalimumab | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): methotrexate + placebo
D: Arm Label: Tocilizumab + Methotrexate; Type: EXPERIMENTAL; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: methotrexate | Arm Label: Tocilizumab + Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: tocilizumab [RoActemra/Actemra], Drug: placebo | Intervention Type: DRUG; Name: tocilizumab [RoActemra/Actemra]; Assigned to Arm(s): Tocilizumab + Methotrexate, Tocilizumab + Placebo | Intervention Type: DRUG; Name: methotrexate; Assigned to Arm(s): Tocilizumab + Methotrexate | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Tocilizumab + Placebo

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Efficacy of Escitalopram in the Treatment of Internet Addiction
Brief Summary: The purpose of this study was to determine whether Lexapro (Escitalopram) is safe and effective in treating problematic internet use.


Options:
A: Arm Label: duloxetine; Type: EXPERIMENTAL; Interventions: Drug: duloxetine | Arm Label: citalopram; Type: ACTIVE_COMPARATOR; Interventions: Drug: citalopram | Arm Label: fluoxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: fluoxetine | Arm Label: paroxetine; Type: ACTIVE_COMPARATOR; Interventions: Drug: paroxetine | Arm Label: sertraline; Type: ACTIVE_COMPARATOR; Interventions: Drug: sertraline | Intervention Type: DRUG; Name: duloxetine; Assigned to Arm(s): duloxetine | Intervention Type: DRUG; Name: fluoxetine; Assigned to Arm(s): fluoxetine | Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): citalopram | Intervention Type: DRUG; Name: paroxetine; Assigned to Arm(s): paroxetine | Intervention Type: DRUG; Name: sertraline; Assigned to Arm(s): sertraline
B: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: citalopram | Intervention Type: DRUG; Name: citalopram; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1
C: Arm Label: Single Arm; Type: EXPERIMENTAL; Interventions: Drug: Escitalopram | Intervention Type: DRUG; Name: Escitalopram; Assigned to Arm(s): Single Arm
D: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Citalopram (Celexa) | Intervention Type: DRUG; Name: Citalopram (Celexa); Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): 1

Answer: C
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Clinical and Quality-of-Life Outcomes After Autologous Fascial Sling and Tension-Free Vaginal Tape: a Prospective Randomized Trial
Brief Summary: The objective of the study was to evaluate the impact AFS and TVT procedures on quality-of-life in incontinent women.


Options:
A: Arm Label: Burch; Type: OTHER; Interventions: Procedure: Burch Modified Tanagho | Arm Label: Sling; Type: OTHER; Interventions: Procedure: Autologous Fascia Sling | Intervention Type: PROCEDURE; Name: Burch Modified Tanagho; Assigned to Arm(s): Burch | Intervention Type: PROCEDURE; Name: Autologous Fascia Sling; Assigned to Arm(s): Sling
B: Arm Label: 2; Type: N/A; Interventions: Procedure: AFS and TVT | Intervention Type: PROCEDURE; Name: AFS and TVT; Assigned to Arm(s): 2
C: Arm Label: Autologous Fascial Sling; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Autologous fascial sling | Arm Label: TVT; Type: ACTIVE_COMPARATOR; Interventions: Procedure: TVT | Arm Label: Pelvicol; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Pelvicol | Intervention Type: PROCEDURE; Name: Autologous fascial sling; Assigned to Arm(s): Autologous Fascial Sling | Intervention Type: PROCEDURE; Name: TVT; Assigned to Arm(s): TVT | Intervention Type: PROCEDURE; Name: Pelvicol; Assigned to Arm(s): Pelvicol
D: Arm Label: 1; Type: ACTIVE_COMPARATOR; Interventions: Procedure: retropubic mid-urethral sling (TVT) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Procedure: transobturator mid-urethral sling (TVT-O and the Monarc) | Intervention Type: PROCEDURE; Name: retropubic mid-urethral sling (TVT); Assigned to Arm(s): 1 | Intervention Type: PROCEDURE; Name: transobturator mid-urethral sling (TVT-O and the Monarc); Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Exploring Integrative Medicine for Back and Neck Pain - A Pragmatic Randomized Clinical Pilot Trial
Brief Summary: Research over the last years have reported an increased popularity of complementary therapies (CTs) and an integration of CTs into mainstream medical settings, health care organizations and insurance plans. These trends may present both new challenges and new opportunities for health care provision. In Sweden and elsewhere, major challenges include the great variety and quality of CT provision within health care and a lack of national and international recommendations of how integrations of CTs with conventional care should be modelled, i.e. lack of conceptual models for delivering integrative medicine (IM). This may partly be a result of a scarce evidence base in support of IM provision within public health care services, e.g. lack of IM compared to usual care in randomised clinical trials. It remains largely unknown whether comprehensive models of IM are clinically or cost effectively different from conventional care provision.

Back and neck pain are costly, conventionally managed in primary care and two of the most common conditions treated by CTs. We have developed a comprehensive collaborative consensus model for IM adapted to Swedish primary care. The aim of this pilot study was to explore the feasibility of a pragmatic randomised clinical trial to investigate the effectiveness of the IM model versus conventional primary care in the management of patients with non-specific back/neck pain.


Options:
A: Arm Label: French ear acupuncture; Type: EXPERIMENTAL; Interventions: Device: French ear acupuncture | Arm Label: Sham Ultrasound; Type: PLACEBO_COMPARATOR; Interventions: Other: Sham Ultrasound | Intervention Type: DEVICE; Name: French ear acupuncture; Assigned to Arm(s): French ear acupuncture | Intervention Type: OTHER; Name: Sham Ultrasound; Assigned to Arm(s): Sham Ultrasound
B: Arm Label: Usual care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Usual care | Arm Label: Integrative care; Type: ACTIVE_COMPARATOR; Interventions: Procedure: Integrative care | Intervention Type: PROCEDURE; Name: Integrative care; Assigned to Arm(s): Integrative care | Intervention Type: PROCEDURE; Name: Usual care; Assigned to Arm(s): Usual care
C: Intervention Type: PROCEDURE; Name: acupuncture; Assigned to Arm(s): N/A
D: Arm Label: Usual care; Type: NO_INTERVENTION; Interventions: N/A | Arm Label: non needle control; Type: PLACEBO_COMPARATOR; Interventions: Procedure: Accupuncture | Arm Label: Acupuncture - Standardized Points; Type: SHAM_COMPARATOR; Interventions: Procedure: Accupuncture | Arm Label: Accupunture - Experimental Points; Type: EXPERIMENTAL; Interventions: Procedure: Accupuncture | Intervention Type: PROCEDURE; Name: Accupuncture; Assigned to Arm(s): Accupunture - Experimental Points, Acupuncture - Standardized Points, non needle control

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect Of Addition of Oral Montelukast to Standard Treatment in Acute Moderate to Severe Asthma in Children Between 5-15 Years of Age - A Randomized, Double Blind, Placebo Controlled Trial
Brief Summary: Available evidences show a role of oral montelukast in acute asthma. Safety of oral montelukast is well established in children, as evidenced by use of oral montelukast in long term management of asthma.

Therefore, the investigators planned this study to see the effect of oral montelukast as add on therapy to standard treatment in acute moderate to severe asthma in children between 5-15 years of age.

HYPOTHESIS:

Addition of single dose of oral montelukast to standard therapy in acute moderate to severe asthma in children aged 5-15 years will reduce the modified pulmonary index score to less than 9 in 90% children compared to 70% in children receiving a placebo.


Options:
A: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: placebo (unspecified) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: montelukast sodium | Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Comparator: placebo (unspecified); Assigned to Arm(s): 1
B: Intervention Type: DRUG; Name: rhDNAse (pulmozyme); Assigned to Arm(s): N/A
C: Intervention Type: DEVICE; Name: Integrated Care Pathway; Assigned to Arm(s): N/A
D: Arm Label: A1; Type: ACTIVE_COMPARATOR; Interventions: Drug: montelukast | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: montelukast; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A2

Answer: D
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect Of Addition of Oral Montelukast to Standard Treatment in Acute Moderate to Severe Asthma in Children Between 5-15 Years of Age - A Randomized, Double Blind, Placebo Controlled Trial
Brief Summary: Available evidences show a role of oral montelukast in acute asthma. Safety of oral montelukast is well established in children, as evidenced by use of oral montelukast in long term management of asthma.

Therefore, the investigators planned this study to see the effect of oral montelukast as add on therapy to standard treatment in acute moderate to severe asthma in children between 5-15 years of age.

HYPOTHESIS:

Addition of single dose of oral montelukast to standard therapy in acute moderate to severe asthma in children aged 5-15 years will reduce the modified pulmonary index score to less than 9 in 90% children compared to 70% in children receiving a placebo.


Options:
A: Arm Label: Montelukast 7 mg; Type: EXPERIMENTAL; Interventions: Drug: montelukast sodium | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: placebo | Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): Montelukast 7 mg | Intervention Type: DRUG; Name: placebo; Assigned to Arm(s): Placebo
B: Arm Label: A1; Type: ACTIVE_COMPARATOR; Interventions: Drug: montelukast | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: montelukast; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A2
C: Arm Label: 1; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: placebo (unspecified) | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: montelukast sodium | Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Comparator: placebo (unspecified); Assigned to Arm(s): 1
D: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: Montelukast plus prednisolone | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Drug: Prednisolone | Intervention Type: DRUG; Name: Montelukast plus prednisolone; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Prednisolone; Assigned to Arm(s): 2

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Effect Of Addition of Oral Montelukast to Standard Treatment in Acute Moderate to Severe Asthma in Children Between 5-15 Years of Age - A Randomized, Double Blind, Placebo Controlled Trial
Brief Summary: Available evidences show a role of oral montelukast in acute asthma. Safety of oral montelukast is well established in children, as evidenced by use of oral montelukast in long term management of asthma.

Therefore, the investigators planned this study to see the effect of oral montelukast as add on therapy to standard treatment in acute moderate to severe asthma in children between 5-15 years of age.

HYPOTHESIS:

Addition of single dose of oral montelukast to standard therapy in acute moderate to severe asthma in children aged 5-15 years will reduce the modified pulmonary index score to less than 9 in 90% children compared to 70% in children receiving a placebo.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: montelukast sodium | Intervention Type: DRUG; Name: montelukast sodium; Assigned to Arm(s): 1
B: Arm Label: A1; Type: ACTIVE_COMPARATOR; Interventions: Drug: montelukast | Arm Label: A2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: montelukast; Assigned to Arm(s): A1 | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): A2
C: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: montelukast | Arm Label: 2; Type: PLACEBO_COMPARATOR; Interventions: Drug: Comparator: Placebo | Intervention Type: DRUG; Name: montelukast; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Comparator: Placebo; Assigned to Arm(s): 2
D: Intervention Type: DRUG; Name: Montelukast (drug); Assigned to Arm(s): N/A

Answer: B
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomised Controlled Trial to Investigate the Effect of a Structured Educational Programme on Physical Activity Levels and Glucose Tolerance in People With Impaired Glucose Tolerance
Brief Summary: This study is a three-armed randomised controlled trial that aims to determine the effect of a structured educational programme on physical activity levels and glucose tolerance in individuals with impaired glucose tolerance (IGT). The educational programme is designed to promote physical activity by targeting perceptions and knowledge of IGT, exercise self-efficacy, and self-regulatory skills. The study will also investigate whether the effectiveness of the educational programme at promoting self-regulatory skills and physical activity is enhanced by the inclusion of a pedometer and personalised step/day goals.


Options:
A: Arm Label: 1; Type: EXPERIMENTAL; Interventions: Behavioral: PREPARE with pedometer | Arm Label: 2; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: PREPARE | Intervention Type: BEHAVIORAL; Name: PREPARE with pedometer; Assigned to Arm(s): 1 | Intervention Type: BEHAVIORAL; Name: PREPARE; Assigned to Arm(s): 2
B: Arm Label: Lifestyle Intervention; Type: EXPERIMENTAL; Interventions: Behavioral: Lifestyle Intervention | Arm Label: Diabetes Support and Education; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Diabetes Support and Education | Intervention Type: BEHAVIORAL; Name: Lifestyle Intervention; Assigned to Arm(s): Lifestyle Intervention | Intervention Type: BEHAVIORAL; Name: Diabetes Support and Education; Assigned to Arm(s): Diabetes Support and Education
C: Arm Label: Lifestyle coaching; Type: EXPERIMENTAL; Interventions: Behavioral: Weight Watchers | Arm Label: Lifestyle counseling; Type: ACTIVE_COMPARATOR; Interventions: Behavioral: Weight Watchers, Behavioral: National Diabetes Education Program | Intervention Type: BEHAVIORAL; Name: Weight Watchers; Assigned to Arm(s): Lifestyle coaching, Lifestyle counseling | Intervention Type: BEHAVIORAL; Name: National Diabetes Education Program; Assigned to Arm(s): Lifestyle counseling
D: Arm Label: Short Message Service (SMS); Type: EXPERIMENTAL; Interventions: Behavioral: Short Message Service (SMS) | Arm Label: Standard usual care; Type: NO_INTERVENTION; Interventions: N/A | Intervention Type: BEHAVIORAL; Name: Short Message Service (SMS); Assigned to Arm(s): Short Message Service (SMS)

Answer: A
Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Double Blind, Placebo Controlled Phase 3 Study of the Efficacy of an Investigational Vero Cell-Derived Influenza Vaccine (VCIV) to Prevent Culture Confirmed Influenza Infection (CCII)
Brief Summary: The primary purpose of this study is to demonstrate the efficacy of an investigational Vero-cell derived influenza vaccine to prevent infection in an adult population with an influenza virus that is antigenically similar to one of the three strains in the vaccine. All subjects will be randomized to receive a single 0.5 ml intramuscular injection from one of three lots of seasonal Vero-cell derived influenza vaccine or saline placebo. Subjects will be monitored for 180 days following vaccination for occurrence of adverse events. For determining antibody response, subjects will have one blood draw before and one blood draw 21 days after vaccination.


Options:
A: Intervention Type: BIOLOGICAL; Name: Fluarix vaccine; Assigned to Arm(s): N/A
B: Arm Label: VAX128; Type: EXPERIMENTAL; Interventions: Biological: VAX128 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: VAX128; Assigned to Arm(s): VAX128 | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo
C: Arm Label: Influenza vaccine; Type: EXPERIMENTAL; Interventions: Biological: Inactivated seasonal influenza vaccine (split virus, Vero cell-derived) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Other: Phosphate buffered saline | Intervention Type: BIOLOGICAL; Name: Inactivated seasonal influenza vaccine (split virus, Vero cell-derived); Assigned to Arm(s): Influenza vaccine | Intervention Type: OTHER; Name: Phosphate buffered saline; Assigned to Arm(s): Placebo
D: Arm Label: CCI; Type: EXPERIMENTAL; Interventions: Biological: Cell culture-derived influenza vaccine | Arm Label: IVV; Type: EXPERIMENTAL; Interventions: Biological: Egg-derived influenza virus vaccine | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Biological: Placebo | Intervention Type: BIOLOGICAL; Name: Cell culture-derived influenza vaccine; Assigned to Arm(s): CCI | Intervention Type: BIOLOGICAL; Name: Egg-derived influenza virus vaccine; Assigned to Arm(s): IVV | Intervention Type: BIOLOGICAL; Name: Placebo; Assigned to Arm(s): Placebo

Answer: C